1.95

2.01% -0.04

Caribou Biosciences Inc (CRBU)

Overview News Price History Option Chain Financials Why CRBU Down? Discussions Forecast

Caribou Biosciences Inc stock is traded at $1.95, with a volume of 1.08M. It is down -2.01% in the last 24 hours and down -2.50% over the past month. Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.

Previous Close:

$1.99

Open:

$1.99

24h Volume:

1.08M

Relative Volume:

0.97

Market Cap:

$180.65M

Revenue:

$34.48M

Net Income/Loss:

$-102.07M

P/E Ratio:

-1.0714

EPS:

-1.82

Net Cash Flow:

$-104.90M

1W Performance:

-30.11%

1M Performance:

-2.50%

6M Performance:

-42.48%

1Y Performance:

-62.64%

1-Day Range:

$1.93

$2.0892

1-Week Range:

$1.93

$2.71

52-Week Range:

$1.50

$8.33

Caribou Biosciences Inc Stock (CRBU) Company Profile

Name

Caribou Biosciences Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

510-982-6030

Address

2929 7TH STREET, SUITE 105, BERKELEY

Employee

137

Twitter

Next Earnings Date

Latest SEC Filings

CRBU's Discussions on Twitter

Compare CRBU with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRBU	1.95	180.65M	34.48M	-102.07M	-104.90M	-1.82
VRTX	467.79	119.83B	10.63B	-479.80M	-1.35B	13.33
REGN	761.02	83.28B	13.85B	4.65B	3.32B	35.06
ARGX	564.78	33.74B	1.86B	-40.29M	-1.28B	-4.16
ALNY	230.27	30.38B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.65	24.08B	3.30B	-501.07M	1.03B	11.54

Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-11-23	Initiated	Truist	Buy
Feb-18-22	Initiated	RBC Capital Mkts	Outperform
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-30-21	Initiated	H.C. Wainwright	Buy
Nov-15-21	Upgrade	Citigroup	Neutral → Buy
Aug-17-21	Initiated	BofA Securities	Buy
Aug-17-21	Initiated	Citigroup	Neutral
Aug-17-21	Initiated	SVB Leerink	Outperform

View All

Caribou Biosciences Inc Stock (CRBU) Latest News

08:02 AM

The Rosen Law Firm, P.A. Announces Proposed Class Action - GlobeNewswire

08:02 AM

08:00 AM

The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Caribou Biosciences, Inc. – CRBU - GlobeNewswire Inc.

08:00 AM

Nov 15, 2024

Steven Cohen's Strategic Acquisition in Caribou Biosciences Inc - GuruFocus.com

Nov 15, 2024

Caribou Biosciences (NASDAQ:CRBU) Receives Buy Rating from HC Wainwright - MarketBeat

Nov 15, 2024

PFM Health Sciences, LP Increases Stake in Caribou Biosciences I - GuruFocus.com

Nov 15, 2024

Nov 13, 2024

Caribou Biosciences' SWOT analysis: biotech stock's potential amid clinical trials - Investing.com Australia

Nov 13, 2024

Nov 12, 2024

Caribou Biosciences, Inc. (NASDAQ:CRBU) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance

Nov 10, 2024

Nov 09, 2024

Caribou Biosciences (NASDAQ:CRBU) Announces Quarterly Earnings Results - MarketBeat

Nov 09, 2024

Caribou Biosciences (NASDAQ:CRBU) vs. Sutro Biopharma (NASDAQ:STRO) Financial Analysis - Defense World

Nov 09, 2024

Nov 08, 2024

Caribou Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 08, 2024

Nov 06, 2024

Caribou Biosciences earnings beat by $0.07, revenue fell short of estimates - Investing.com UK

Nov 06, 2024

Caribou Biosciences reports Q3 EPS (38c), consensus (45c) - TipRanks

Nov 06, 2024

Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update - StockTitan

Nov 06, 2024

CRISPR Technology Market Report 2024, with Profiles of Major Players Agilent Technologies, Beam Therapeutics, Caribou Biosciences, Crispr Therapeutics, Danaher, Genscript, Lonza and MoreResearchAndMarkets.com | FinancialContent Business Page - Financial Content

Nov 06, 2024

Nov 05, 2024

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry - Simply Wall St

Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Caribou Biosciences Inc - GuruFocus.com

Nov 05, 2024

Nov 03, 2024

Critical Analysis: Caribou Biosciences (NASDAQ:CRBU) & Titan Pharmaceuticals (NASDAQ:TTNP) - Defense World

Nov 03, 2024

Oct 31, 2024

Is Caribou Biosciences (CRBU) a Promising Gene Editing Stock? - Insider Monkey

Oct 31, 2024

Oct 30, 2024

10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds - Insider Monkey

Oct 30, 2024

Oct 22, 2024

Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Bought by Exchange Traded Concepts LLC - Defense World

Oct 22, 2024

Oct 17, 2024

STATE STREET CORP's Strategic Acquisition in Caribou Biosciences Inc - GuruFocus.com

Oct 17, 2024

Following a 49% decline over last year, recent gains may please Caribou Biosciences, Inc. (NASDAQ:CRBU) institutional owners - Simply Wall St

Oct 17, 2024

Oct 16, 2024

Its Stock Has Paid Off Big Time For Caribou Biosciences Inc - SETE News

Oct 16, 2024

Oct 15, 2024

How to interpret Caribou Biosciences Inc (CRBU)’s stock chart patterns - US Post News

Oct 15, 2024

Oct 14, 2024

Daily Market Movement: Caribou Biosciences Inc (CRBU) Sees a 5.56 Increase, Closing at 1.90 - The Dwinnex

Oct 14, 2024

Oct 10, 2024

Dimensional Fund Advisors LP Has $4.30 Million Stock Position in Caribou Biosciences, Inc. (NASDAQ:CRBU) - MarketBeat

Oct 10, 2024

Oct 09, 2024

A better buy-in window may exist right now for Caribou Biosciences Inc (CRBU) - SETE News

Oct 09, 2024

Oct 08, 2024

Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Purchased by Green Alpha Advisors LLC - Defense World

Oct 08, 2024